PLD3 Knockout HAP1 Cell Line

The choice depends on whether you are studying PLD3's role as a lysosomal 5'-3' exonuclease (notably not a classical phospholipase D despite the name) or modeling late-onset Alzheimer's disease (LOAD) and spinocerebellar ataxia 46 (SCA46). The Knockout line is the standard tool for asking whether PLD3 is required for these activities — PLD3 is a lysosomal type II membrane protein that, despite belonging to the PLD superfamily, functions as a single-stranded DNA 5'-3' exonuclease rather than as a phospholipase. Overexpression is useful for studying PLD3 in autophagy or for testing disease-associated mutations. Important note: PLD3 mechanistically differs from PLD1 and PLD2 — PLD3 does not produce phosphatidic acid but instead processes nucleic acid substrates. PLD3 mutations are associated with late-onset Alzheimer's disease risk (V232M variant) and autosomal dominant SCA46. Rescue with wild-type or catalytically-dead PLD3 enables structure-function studies. The knockout is valuable for studying lysosomal nucleic acid metabolism, neuroinflammation, and Alzheimer's disease genetics.

Primary applications: • 5'-3' exonuclease activity: in vitro DNA exonuclease activity assays using defined ssDNA substrates to characterize PLD3's nuclease function — distinct from classical phospholipase D activities. • Lysosomal nucleic acid handling: lysosomal DNA accumulation analysis given PLD3's role in lysosomal ssDNA degradation. • Alzheimer's disease modeling: rescue with V232M (LOAD risk variant) and other patient-derived PLD3 mutations for genotype-function studies. • Neuroinflammation studies: cGAS-STING pathway readouts given PLD3's role in restricting cytosolic DNA-driven innate immunity through lysosomal DNA clearance. EDITGENE recommends this model for researchers investigating lysosomal nucleic acid biology, Alzheimer's disease genetics, and PLD3-mediated innate immunity regulation.

Yes. PLD3 rescue experiments require attention to lysosomal targeting and exonuclease activity: • Construct design: use a codon-modified PLD3 sequence with a small luminal (C-terminal) tag (FLAG, HA). PLD3 is a type II membrane protein with N-terminal cytoplasmic tail, single transmembrane domain, and luminal catalytic domain containing two HKD motifs — preserve all elements. • Catalytically-dead rescue: HKD motif mutations (typically conserved H or K residues) abolish exonuclease activity and serve as the standard specificity control. • Lysosomal localization validation: confirm lysosomal localization by LAMP1 co-staining before functional assays. • Disease mutation rescue: V232M (LOAD risk) and SCA46-associated PLD3 mutations enable disease genotype-function studies. • Functional readout: rescue should restore ssDNA exonuclease activity and lysosomal DNA clearance. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.